Blue Handkerchief Public Welfare Parkinson's Disease Network Series Academic Conference, the last phase of 2021 successfully concluded

Parkinson's disease (PD) is a common neurological disease that usually starts after 60 years of age, which seriously affects the quality of life of patients and has a high disability rate
.

According to statistics , there are currently about 5 million Parkinson's disease patients in the world, and about half of them are in China

Parkinson's disease (PD) is a common neurological disease that usually starts after 60 years of age, which seriously affects the quality of life of patients and has a high disability rate

The live special invitation invited Shanghai Jiaotong University Affiliated Ruijin Hospital, deputy director of the Department of Neurology, Department of Neurology, members of the specialist committee of Shanghai Medical Association, Chinese Medical Association credits will neuropathy, Parkinson's disease and movement disorders study group members Professor Xiao Qin Ruijin Hospital and Professor Mao Zhiqi, chief physician of neurosurgery at the First Medical Center of the Chinese People's Liberation Army General Hospital, gave live lectures on the contents of "Treatment of Parkinson's Disease Combined with Medical Diseases" and " CT Positioning DBS Surgical Treatment of Elderly Patients " .
The live broadcast event was supported by the public welfare of Lipin Pharmaceutical Co.
, Ltd.

 

 

Professor Xiao Qin proposed that the diagnosis and treatment training for Parkinson’s disease should not only target Parkinson’s disease specialists and neurology doctors, but should even be extended to internal medicine doctors.

Everyone needs to identify patients when merging internal medicine and conduct targeted treatments.
Sexual treatment

Professor Xiao Qin proposed that the diagnosis and treatment training for Parkinson’s disease should not only target Parkinson’s disease specialists and neurology doctors, but should even be extended to internal medicine doctors.

The third is the complications of heart disease.
For Parkinson’s disease patients, it is necessary to pay attention to the contraindications of cardiomyopathy, arrhythmia , acute myocardial infarction and other diseases; in addition, it also introduces melanoma, diarrhea, peripheral edema, and epilepsy.
Precautions for medication with complications such as anemia and anemia
.

Professor Xiao proposed that as a clinician, we should "do research with problems".

The third is the complications of heart disease.

 

Professor Mao Zhiqi introduced the "CT Oriented DBS Surgical Treatment for Elderly Patients", and analyzed the treatment cycle of an 82-year-old patient with Parkinson's disease.
As a primary Parkinson's disease patient, DBS was performed according to the patient's request.
During the operation, a detailed surgical plan was formulated.
According to the patient's physical condition, general anesthesia was performed and intraoperative electrophysiological testing was performed.
After the operation, the electrode position was found to be very good.
After two weeks, the start-up test improved significantly, and there were basically no side effects
.

The video sent back by the family showed that the patient was able to eat on his own, walked independently, and basically achieved self-care; after half a year, he could engage in outdoor activities.

Professor Mao Zhiqi introduced the "CT Oriented DBS Surgical Treatment for Elderly Patients", and analyzed the treatment cycle of an 82-year-old patient with Parkinson's disease.

 

Parkinson's Disease Network Conference Series 2021 years a total hold 5 games, the cumulative number of viewers of 9 million people
.

Parkinson's Disease Network Conference Series 2021 years a total hold 5 games, the cumulative number of viewers of 9 million people
.

 

 

About "Blue Handkerchief Public Welfare Project"

About "Blue Handkerchief Public Welfare Project" About "Blue Handkerchief Public Welfare Project"

"Blue Handkerchief Public Welfare Project"-Parkinson’s Disease Medical Development and Patient Care Special Action Through a series of activities such as science popularization, doctor training, free consultations and patient assistance, the public's awareness of Parkinson's disease will be improved, the level of diagnosis and treatment of Parkinson's disease by grassroots doctors will be improved, and the phenomenon of misdiagnosis, missed diagnosis and delayed treatment of Parkinson's disease patients in our country will be further reduced.
Occurs, improving the quality of life of Parkinson’s disease patients
.

"Blue Handkerchief Public Welfare Project"-Parkinson’s Disease Medical Development and Patient Care Special Action Through a series of activities such as science popularization, doctor training, free consultations and patient assistance, the public's awareness of Parkinson's disease will be improved, the level of diagnosis and treatment of Parkinson's disease by grassroots doctors will be improved, and the phenomenon of misdiagnosis, missed diagnosis and delayed treatment of Parkinson's disease patients in our country will be further reduced.
Occurs, improving the quality of life of Parkinson’s disease patients
.

In 2021, the "Blue Handkerchief Public Welfare Project" has launched a number of popular science and free clinic activities
.

In order to encourage more doctors to participate in the project and provide more professional services for the public and Parkinson’s disease patients, the project integrates multiple resources such as Kuaishou, Metz Medicine, Miaoshou Doctors, Lianjia, local charities and government departments, to provide a group of doctors.
Provide professional support in many aspects such as the production of popular science content, the operation of doctors' personal accounts, the planning and organization of popular science/patient education activities, and the transformation of scientific research results
.

In 2021, the "Blue Handkerchief Public Welfare Project" has launched a number of popular science and free clinic activities
.
In order to encourage more doctors to participate in the project and provide more professional services for the public and Parkinson’s disease patients, the project integrates multiple resources such as Kuaishou, Metz Medicine, Miaoshou Doctors, Lianjia, local charities and government departments, to provide a group of doctors.
Provide professional support in many aspects such as the production of popular science content, the operation of doctors' personal accounts, the planning and organization of popular science/patient education activities, and the transformation of scientific research results
.

This charity event was supported by a donation from Lipin Pharmaceutical
.
Lipin Pharmaceutical is the first high-tech enterprise in Fujian Province to pass the Sino-US GMP dual certification.
The company was founded in 2012 by a team of returned doctors led by national special experts.
It has long been committed to the research and development of Parkinson's disease and supports the training of young doctors.

.
Lipin has multiple core technology platforms such as innovative oral film technology platform, high-end sustained and controlled release formulation technology platform, innovative microsphere formulation technology platform, and solubilizing formulation technology platform.
The company's quality system is in line with international standards, and product quality has reached international standards
.
Lisuo® developed and produced by the company is the only domestically produced, dual-batch pramipexole hydrochloride sustained-release tablet in China and the United States, providing patients with a more convenient and safer treatment plan
.

This charity event was supported by a donation from Lipin Pharmaceutical
.
Lipin Pharmaceutical is the first high-tech enterprise in Fujian Province to pass the Sino-US GMP dual certification.
The company was founded in 2012 by a team of returned doctors led by national special experts.
It has long been committed to the research and development of Parkinson's disease and supports the training of young doctors.

.
Lipin has multiple core technology platforms such as innovative oral film technology platform, high-end sustained and controlled release formulation technology platform, innovative microsphere formulation technology platform, and solubilizing formulation technology platform.
The company's quality system is in line with international standards, and product quality has reached international standards
.
Lisuo® developed and produced by the company is the only domestically produced, dual-batch pramipexole hydrochloride sustained-release tablet in China and the United States, providing patients with a more convenient and safer treatment plan
.

 

 

Leave a message here